These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
582 related items for PubMed ID: 37151876
1. Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine. Chen H, Ye C, Wu C, Zhang J, Xu L, Wang X, Xu C, Zhang J, Guo Y, Yao Q. Int J Biol Sci; 2023; 19(7):2097-2113. PubMed ID: 37151876 [Abstract] [Full Text] [Related]
4. Integration of microbiome, metabolomics and transcriptome for in-depth understanding of berberine attenuates AOM/DSS-induced colitis-associated colorectal cancer. Wang M, Ma Y, Yu G, Zeng B, Yang W, Huang C, Dong Y, Tang B, Wu Z. Biomed Pharmacother; 2024 Oct; 179():117292. PubMed ID: 39151314 [Abstract] [Full Text] [Related]
9. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. Shi Y, Hu J, Geng J, Hu T, Wang B, Yan W, Jiang Y, Li J, Liu S. Biomed Pharmacother; 2018 Nov; 107():1556-1563. PubMed ID: 30257374 [Abstract] [Full Text] [Related]
10. Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites. Jing W, Dong S, Luo X, Liu J, Wei B, Du W, Yang L, Luo H, Wang Y, Wang S, Lu H. Pharmacol Res; 2021 Feb; 164():105358. PubMed ID: 33285228 [Abstract] [Full Text] [Related]
13. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. Yue SJ, Liu J, Wang AT, Meng XT, Yang ZR, Peng C, Guan HS, Wang CY, Yan D. Am J Physiol Endocrinol Metab; 2019 Jan 01; 316(1):E73-E85. PubMed ID: 30422704 [Abstract] [Full Text] [Related]
19. Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids. Yao Y, Chen H, Yan L, Wang W, Wang D. Biomed Pharmacother; 2020 Nov 01; 131():110669. PubMed ID: 32937246 [Abstract] [Full Text] [Related]